Mission

At Fibrodyne, we’re on a journey to improve the lives of the millions around the world who are affected by scarring or age-related skin changes. Our breakthrough in fibroblast (skin cell) biology, which unlocks the power of the skin to regenerate itself, makes easy, simple and truly effective scar elimination accessible and affordable to all. Already proven to be safe and effective for acne scars, our unique Advanced Therapy is already being extended to the treatment of more extensive scars associated with surgery and trauma.

WHY

Disease. Injury. Surgery. Age. They can all cause scarring. And every scar, irrespective of its size or type, can – and often does – cause significant physical, psychological or emotional distress to those who live with them. Yet, despite the best efforts of the medical and cosmetic industries, genuinely effective remedies have proved elusive. Although some treatments exist, they are often complicated and short-term, while many such treatments, provided by the cosmetics industry, are beyond the financial means of most.

A skin restoration solution that is simple, permanent and affordable by all would be welcomed across the globe. Fibrodyne’s unique technique has been developed to meet this need.

HOW

It is well known that cells called fibroblasts make the collagen protein that gives skin its structure. But the Fibrodyne team have shown that different types of fibroblasts play different roles in skin restoration. By removing fibroblasts from healthy skin, and injecting them into the same person’s scar tissue, the scar can be restored to normal appearance and function.

It is a fast and inexpensive procedure that is about to undergo trials in acne and more extensive scars associated with trauma and surgery.

FOR
PATIENTS

Scars can have profound, often life-impairing, effects on those who have to live with them. Yet, for most people, living with a scar is the only practical choice. Currently, available treatments, either medical or through cosmetic surgery, are not only limited in their efficacy, but are often extremely expensive. Acne, for example, can require multiple treatments to deliver noticeable improvement, costing up to £10,000.

Fibrodyne’s breakthrough radically changes this situation. The company’s Advanced Medical Therapy, based on its recent fibroblast research, successfully shifts the treatment philosophy from scar repair to skin regeneration, providing a safe, simple and genuinely effective route to permanently improved skin. No longer must those affected by scarring undergo a complicated and expensive procedure to have their condition treated. Now, anyone troubled by scars, whether caused by injury, surgery or disease, has access to a simple, single-step medical procedure with permanent results – results with the potential to transform their life.

SEE MORE
Image

FOR
PATIENTS

Scars can have profound, often life-impairing, effects on those who have to live with them. Yet, for most people, living with a scar is the only practical choice. Currently, available treatments, either medical or through cosmetic surgery, are not only limited in their efficacy, but are often extremely expensive. Acne, for example, can require multiple treatments to deliver noticeable improvement, costing up to £10,000.

Fibrodyne’s breakthrough radically changes this situation. The company’s Advanced Medical Therapy, based on its recent fibroblast research, successfully shifts the treatment philosophy from scar repair to skin regeneration, providing a safe, simple and genuinely effective route to permanently improved skin. No longer must those affected by scarring undergo a complicated and expensive procedure to have their condition treated. Now, anyone troubled by scars, whether caused by injury, surgery or disease, has access to a simple, single-step medical procedure with permanent results – results with the potential to transform their life.

SEE MORE

FOR
INVESTORS

The global market for skin treatments is extremely large and growing rapidly. The annual US market for anti-scarring treatments, for example, is estimated at $12 billion, while the global market is expected to reach almost $40 billion by 2026, with a CAGR of 9.9%. The commercial and social implications for an Advanced Therapy which is not only proven to deliver significantly better results than existing treatments, but which is also simple and accessible to all, are clear.

Fibrodyne’s breakthrough treatment is such a therapy. Already undergoing First-in-Human trials for the treatment of acne (one of today’s biggest areas of demand), the Fibrodyne therapy will be rapidly scaled to meet the demand for treatment of extensive scars associated with self-harm, wounds and burns. All indications to date are that this scale-up will be fast and seamless.

SEE MORE
Image

FOR
INVESTORS

The global market for skin treatments is extremely large and growing rapidly. The annual US market for anti-scarring treatments, for example, is estimated at $12 billion, while the global market is expected to reach almost $40 billion by 2026, with a CAGR of 9.9%. The commercial and social implications for an Advanced Therapy which is not only proven to deliver significantly better results than existing treatments, but which is also simple and accessible to all, are clear.

Fibrodyne’s breakthrough treatment is such a therapy. Already undergoing First-in-Human trials for the treatment of acne (one of today’s biggest areas of demand), the Fibrodyne therapy will be rapidly scaled to meet the demand for treatment of extensive scars associated with self-harm, wounds and burns. All indications to date are that this scale-up will be fast and seamless.

SEE MORE

THE
SCIENCE

The potential of fibroblasts (skin cells) for treating scars has been known for some time. Until now, however, attempts to realise this potential have proved unsuccessful.

Existing approaches to fibroblast treatments are based on the injection of many cells from one person into the scar of another. This results in most cells either being rejected by the patient’s immune system, or accumulating in one site. In short, existing treatments are complicated, slow, unreliable and costly.

Fibrodyne’s insight was to realise that fewer cells, used autologously, could address these issues. If fibroblasts could be isolated from a patient’s skin, and reinjected into the scar site in an uncultured form, rapid skin regeneration would be assured and safe. And so it has proved. It is a bonus, but a big one, that the speed and simplicity of the Fibrodyne breakthrough also dramatically reduces the cost of the process.

SEE MORE
Image

THE
SCIENCE

The potential of fibroblasts (skin cells) for treating scars has been known for some time. Until now, however, attempts to realise this potential have proved unsuccessful.

Existing approaches to fibroblast treatments are based on the injection of many cells from one person into the scar of another. This results in most cells either being rejected by the patient’s immune system, or accumulating in one site. In short, existing treatments are complicated, slow, unreliable and costly.

Fibrodyne’s insight was to realise that fewer cells, used autologously, could address these issues. If fibroblasts could be isolated from a patient’s skin, and reinjected into the scar site in an uncultured form, rapid skin regeneration would be assured and safe. And so it has proved. It is a bonus, but a big one, that the speed and simplicity of the Fibrodyne breakthrough also dramatically reduces the cost of the process.

SEE MORE

OUR TEAM

The Fibrodyne team includes some of the most highly-qualified and experienced professionals in the field of skin research.

With a wide range of complementary skills and interests, they form a creative, scientific and business synergy which is perfectly positioned to realise the full potential of the company’s innovative and disruptive concept.

PROF FIONA
WATT

FRS FMedSci

Fiona Watt is recognised internationally for her research on skin. After gaining her PhD (DPhil) from the University of Oxford, she carried out postdoctoral research at MIT before moving to London to establish her own research group.

Among many honours, she has received the Chanel CE.R.I.E.S. Research Award and the William Montagna Award of the American Society for Investigative Dermatology.

Fiona is a Fellow of the Royal Society, an international member of the National Academy of Sciences and an Honorary Member of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology.

Her current research portfolio includes studies of human epidermal stem cells and an exploration of the role of different fibroblasts in skin restoration.

Image

PROF FIONA
WATT

FRS FMedSci

Fiona Watt is recognised internationally for her research on skin. After gaining her PhD (DPhil) from the University of Oxford, she carried out postdoctoral research at MIT before moving to London to establish her own research group.

Among many honours, she has received the Chanel CE.R.I.E.S. Research Award and the William Montagna Award of the American Society for Investigative Dermatology.

Fiona is a Fellow of the Royal Society, an international member of the National Academy of Sciences and an Honorary Member of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology.

Her current research portfolio includes studies of human epidermal stem cells and an exploration of the role of different fibroblasts in skin restoration.

DR MAGNUS
LYNCH

MA DPhil MRCP

A Consultant Dermatologist and Dermatological Surgeon at Guy’s and St Thomas’ NHS Foundation Trust, Magnus Lynch is also a research group leader at the Centre for Stem Cells and Regenerative Medicine, King’s College London. He graduated in medicine from the University of Cambridge and trained in Dermatology at St John’s Institute of Dermatology, where he also completed a fellowship in Mohs Surgery and advanced Dermatological Surgery.

Magnus obtained his DPhil from the University of Oxford and subsequently undertook postdoctoral work in the
Centre for Stem Cells and Regenerative Medicine. His research interests include the application of single cell and spatial transcriptomic approaches to human skin and understanding the roles of fibroblast populations in
scarring and skin aging.

Image

DR MAGNUS
LYNCH

MA DPhil MRCP

A Consultant Dermatologist and Dermatological Surgeon at Guy’s and St Thomas’ NHS Foundation Trust, Magnus Lynch is also a research group leader at the Centre for Stem Cells and Regenerative Medicine, King’s College London. He graduated in medicine from the University of Cambridge and trained in Dermatology at St John’s Institute of Dermatology, where he also completed a fellowship in Mohs Surgery and advanced Dermatological Surgery.

Magnus obtained his DPhil from the University of Oxford and subsequently undertook postdoctoral work in the
Centre for Stem Cells and Regenerative Medicine. His research interests include the application of single cell and spatial transcriptomic approaches to human skin and understanding the roles of fibroblast populations in
scarring and skin aging.

DR CHRISTINA
PHILIPPEOS

PhD MSC

Christina is a post-doctoral cell biologist at the Centre for Stem Cells and Regenerative Medicine, King’s College London. She obtained a BSc. in Natural and Environmental Sciences from Rand Afrikaans University in South Africa, and after gaining an MSc. in Biochemistry from the University of Johannesburg, she moved to London and obtained her PhD in Cell Biology at King’s College London.

Christina continued her postdoctoral training with Fiona Watt, joining the lab when work on the breakthrough realisation that human skin contains different kinds of fibroblasts had just begun. She is specifically interested in these cells in the context of therapeutic applications for wound repair, tissue regeneration and diseases characterized by excessive scar tissue.

Christina combines her laboratory expertise with experience in cosmetic treatments gained from being a co-director of one of London’s leading aesthetic clinics.

Image

DR CHRISTINA
PHILIPPEOS

PhD MSC

With family origins in Greece, Christina grew up in South Africa, where she gained a BSc. in Natural and Environmental Sciences from Rand Afrikaans University.

After gaining an MSc. in Biochemistry from the University of Johannesburg, she moved to London and obtained her PhD in Cell Biology at King’s College London. She continued her postdoctoral training with Fiona Watt, joining the lab when work on the breakthrough realisation that human skin contains different kinds of fibroblasts had just begun.

Christina combines her laboratory expertise with experience in beauty therapies gained from working in one of London’s leading cosmetic companies.

THE FIBRODYNE
ORIGIN STORY...

X-rays; the selective culturing of bacteria; Penicillin. These are just three of many famous examples of accidental discoveries which have radically altered – and often revolutionised – the direction of medical thinking. Now, Fibrodyne’s Advanced Therapy for scar elimination is set to join their illustrious company.

Why? Because it was an accidental discovery by Fiona Watt that led to the creation of Fibrodyne. In Fiona’s case, it was the discovery that a gene, previously thought to be a marker of epidermal stem cells, was instead expressed by skin fibroblasts. This realisation stimulated research, by Fiona and her team, on fibroblasts. They found that there are different types of fibroblasts in the skin, each with a different function.

To Fiona, the implications of this insight were clear. And extremely exciting. Immediately recognising that her research could form the foundation of a new, and much more effective, approach to treating scars, she teamed up with Christina and Magnus. Fibrodyne was born.

DIFFERENT FIBROBLASTS FOR
DIFFERENT NEEDS